in Nucleic Acid Therapeutics for Human Health


  • HOME
  • R & D
  • OliX Pipeline
  • OLX301A

Age-Related Macular Degeneration (AMD)

  • occurs when the small central portion of the retina, known as the macula, deteriorates
  • The leading cause of severe vision loss in people over age 60 in developed countries
  • Two types : wet AMD (10%) & dry AMD (90%)

Market Potential

  • Leading cause of vision loss globally, no. 1 disease for vision loss in developed countries
  • AMD patients steadily increasing globally, 200 million patients in 2020, 3 million patients expected in 2040.
  • AMD patients in US estimated to be 1.75 million in 2014 (source: All about vision, Understanding AMD 2014)
  • Global market size of AMD drugs in 2013 was KRW 5.5 trillion, forecasted to be KRW 13trillion by 2026
    (source: GlobalData 2018, major 7 countries)

Development Status

  • Animal Efficacy test currently under way in University of Virginia School of Medicine
    (Collaboration with Dr. J . Ambati, Department of Ophthalmology)
  • Outstanding efficacy identified from animal modelswith dry macular degeneration
  • Collaboration and License Agreement with Théa Open Innovation for the treatment of AMD (OLX301A)
  • Expects to submit an IND for a Phase 1 clinical trial in USA